Oncotelic Therapeutics (OTCQB: OTLC), a developer of oncology and immunotherapy products, along with its wholly owned subsidiary Pet2DAO, Inc., has announced that its PDAOAI artificial intelligence-powered drug discovery platform is now accepting registrations for BIO REBOOT. The initiative invites scientists, AI developers, and biotech founders to bring research questions, technical expertise, and drug discovery ideas to the PDAOAI community. Selected projects may be considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning, and clinical development.
The company also revealed that two PDAOAI keynote presentations will be delivered at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for October 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation generated a candidate four-gene signature. Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development.
For stakeholders, the BIO REBOOT registration and conference presentations signal a strategic push to democratize access to AI-driven drug discovery. By inviting external participants, Oncotelic aims to accelerate the identification of novel therapeutic candidates, particularly for cancers with substantial unmet needs and rare pediatric indications. The potential funding and support for selected projects could lower barriers for early-stage researchers, fostering innovation in a space often dominated by large pharmaceutical companies.
The PDAOAI platform's role in generating a four-gene signature for hepatocellular carcinoma, a leading cause of cancer deaths worldwide, underscores its potential to streamline target discovery. If the approach proves successful, it could reduce the time and cost associated with traditional drug development, ultimately bringing new treatments to patients faster. The conference keynotes will provide a platform to showcase these capabilities to a global audience of researchers and industry leaders.
Oncotelic's focus on rare pediatric indications further highlights the importance of its work, as these conditions often receive limited attention from commercial developers. The BIO REBOOT initiative may attract talent and ideas that could lead to therapies for underserved patient populations.
To view the full press release, visit https://ibn.fm/dxB7y. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform delivers wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit www.BioMedWire.com.
